FASN polymorphisms are associated with treatment response and severe hematological toxicity induced by platinum-based chemotherapy among Chinese patients with non-small-cell lung cancer
BACKGROUND: Fatty acid synthase (FASN) is overexpressed in cancer cells, which sustains their elevated demands for membrane synthesis, energy metabolism, and protein biosynthesis. FASN overexpression may serve as a promising therapeutic target for cancer treatment and a key modulator of chemotherapy resistance. This study aimed to explore whether tag single-nucleotide polymorphisms (tag-SNPs) in the FASN gene are related with treatment response and severe chemotherapy toxicity in patients with non-small cell lung cancer (NSCLC) receiving platinum-based regimens. METHODS: A multivariable logistic regression model was applied to evaluate the associations between four tag-SNPs of the FASN gene and clinical outcomes in a cohort of 437 Chinese patients with NSCLC. RESULTS: The variant homozygotes of FASN rs1140616 and rs4246445 were significantly associated with poor treatment response in advanced NSCLC patients undergoing first-line platinum-based chemotherapy compared with wild-type homozygotes. FASN rs1140616, rs2228309, and rs4246445 polymorphisms were significantly related with an increased risk of grade 3-4 thrombocytopenia. FASN rs2228309 variant was linked to a higher incidence of grade 3-4 anemia. CONCLUSION: These findings highlight the critical involvement of the lipid metabolism pathway in platinum chemotherapy resistance and toxicity in NSCLC. Notably, this study addresses a key research gap in the field, as most existing relevant evidence is restricted to in vitro preclinical models.
Authors
- Chao Ling (ORCID: https://orcid.org/0000-0001-5328-4906)
- Zheng Deng
- Mimi Tang
- Pei Cai
- Yi Zheng
Publication Details
- Journal
- Oncology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1159/ocl/aebag022
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00